Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Will The Cancer Tumor Profiling Market Valuation Change Between Now And 2029?
In recent times, the market size of cancer tumor profiling has seen a significant expansion. There is an expected increase from $13 billion in 2024 to $14.97 billion in 2025, showing a compound annual growth rate (CAGR) of 15.1%. The spike during the historical span can be linked to factors such as a rise in cancer cases, advancements in precision medicine initiatives and research partnerships, enhancements in cancer diagnosis and early detection techniques, the offering of diverse targeted therapy choices, and favorable regulations for cancer profiling examinations.
Over the next few years, the cancer tumor profiling market is slated for swift expansion, rocketing to $25.12 billion by 2029 with a compound annual growth rate (CAGR) of 13.8%. This predicted surge is due to factors such as the unfolding of immunotherapy and immunoprofiling in cancer treatment, progression in liquid biopsy and non-invasive tumor profiling techniques, along with the wider use of single-cell sequencing for comprehensive tumor insights. Other contributing factors include broadening of cancer screening and early diagnosis programs, and a growing need for profiling of rare and particular cancer subtypes. The forecast period is also expected to witness several trends like the incorporation of tumor profiling into everyday clinical practices, advancements in multi-omics strategies, harnessing artificial intelligence (AI) and machine learning for data interpretation, personalized medicine and targeted treatment evolution, and progress in genomics and next-generation sequencing (ngs) technologies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp
What Underlying Factors Are Supporting The Cancer Tumor Profiling Market Growth?
The surge in cancer cases worldwide is anticipated to stimulate the expansion of the cancer and tumor profiling market in the future. Cancer is a medical condition that causes a rampant and uncontrolled growth of certain cells which subsequently invades other parts of the body. With the escalating prevalence of cancer, comes a growing need for cancer tumor profiling that allows medical practitioners to accurately ascertain the extent and gravity of the disease. For example, the American Cancer Society, a professional organization based in the US, recorded an increase in cancer diagnoses from 1.9 million new cases in 2023 to 2 million new cases in 2024. Accordingly, the uptrend in global cancer occurrences fuels the development of the cancer and tumor profiling market.
Which Sub-Segments Are Driving Growth Within The Cancer Tumor Profiling Market?
The cancer tumor profilingmarket covered in this report is segmented –
1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types
2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types
4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications
Subsegments:
1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer
What Future-Focused Trends Are Anticipated In The Cancer Tumor Profiling Market?
A notable trend that is emerging with increased prominence in the cancer and tumor profiling market is the heightened focus on research and development activities. Major players in this industry, such as the German company QIAGEN N.V which specialises in sample and assay technology for fields like applied testing, pharmaceutical development, molecular diagnostics and academic research, are keen on strengthening their position by answering consumer demands through rigorous R&D. For example, the company recently announced the Conformitè Europëenne (CE)-marking and commercialization of therascreen PIK3CA RGQ PCR Kit in Europe. This tool is aimed to help in identifying breast cancer patients with PIK3CA mutations. It is essentially a diagnostic assay for detecting an activating mutation in the gene named phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) and is the first of its kind to allow testing from either DNA from plasma specimens or FFPE tissue.
Which Companies Hold A Competitive Edge In The 11 Market?
Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report
Which Region Dominates The Cancer Tumor Profiling Market Today?
North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp
Browse Through More Reports Similar to the Global Cancer Tumor Profiling Market 2025, By The Business Research Company
Cancer Biologics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report
Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Tumor Ablation Therapy Devices Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model